The DOI matches its Crossref record.
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis (MS): 942
Abstract
Purpose: Recent evidence implicates the GI microbiota in the progression of neurological diseases such as Parkinsons Disease1, Multiple Sclerosis and Myasthenia Gravis2. We report three patients with MS diagnoses who achieved durable symptom reversal with FMT for constipation. Methods: Case study observations on three MS cases Results: Case 1: A 30 yr old male with constipation, vertigo and impaired concentration and a concomitant history of MS and trigeminal neuralgia. Neurological symptoms included severe leg weakness and he required a wheelchair and an indwelling urinary catheter. Previous failed treatments included Mexiletine, Tryptanol and β-interferon. The patient underwent 5 FMT infusions for his constipation, with its complete resolution. Interestingly his MS also progressively improved, regaining the ability to walk and facilitating the removal of his catheter. Initially seen as a ‘remission', the patient remains well 15 yrs post-FMT without relapse. Case 2: A 29 yr old wheelchair-bound male with ‘atypical MS' diagnosis and severe, chronic constipation. He reported parasthesia and leg muscle weakness. The patient received 10 days of FMT infusions which resolved his constipation. He also noted progressive improvement in neurological symptoms, regaining the ability to walk following slow resolution of leg parasthesia. Three years on the patient maintains normal motor, urinary and GI function. Case 3: An 80 yr old female presented with severe chronic constipation, proctalgia fugax and severe muscular weakness resulting in difficulty walking, diagnosed as ‘atypical' MS. She received 5 FMT infusions with rapid improvement of constipation and increased energy levels. At eight months she reported complete resolution of bowel symptoms and neurological improvement, now walking long distances unassisted. Two years post-FMT, the patient was asymptomatic. Conclusion: We report reversal of major neurological symptoms in three patients after FMT for their underlying GI symptoms. As MS can follow a relapsing-remitting course, this unexpected discovery was not reported until considerable time had passed to confirm prolonged remission. It is tempting to speculate that FMT achieved eradication of an occult GI pathogen driving MS symptoms. Our finding that FMT can reverse MS-like symptoms suggests a GI infection underpinning these disorders. It is hoped that such serendipitous findings may encourage a new direction in neurological research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an additional relevant study, three MS patients underwent multiple fecal microbiota transplantations (FMT) to treat severe constipation. This treatment reverted the intestinal illness and improved the MS symptoms (147), proving the existence of a gut-brain connection.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [147]
Citations
Cited by
Sorted by citations
The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology
Rutsch, A., Kantsjö, J. B., & Ronchi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604179 · Cited by 821
Therapeutic Potential of Fecal Microbiota Transplantation
Smits, L. P., Bouter, K. E. C., de Vos, W. M., Borody, T. J., & Nieuwdorp, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.058 · Cited by 717
Self-citationThe Gastrointestinal Microbiome: A Review
Barko, P. C., McMichael, M. A., Swanson, K. S., & Williams, D. A. (2018) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14875 · Cited by 750
Fecal microbiota transplantation and emerging applications
Borody, T. J., & Khoruts, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.244 · Cited by 677
Self-citationFecal Microbiota Transplantation in Neurological Disorders
Vendrik, K. E. W., Ooijevaar, R. E., de Jong, P. R. C., Laman, J. D., van Oosten, B. W., van Hilten, J. J., Ducarmon, Q. R., Keller, J. J., Kuijper, E. J., & Contarino, M. F. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00098 · Cited by 413
“FMT studies in patients (Table 2) Currently, there are only two case reports/series on effects of FMT on MS symptoms and disease progression (Borody et al., 2011; Makkawi et al., 2018).”
BackgroundSystematic Review: Adverse Events of Fecal Microbiota Transplantation
Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., & Wang, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161174 · Cited by 416
Kanmani, S., & Koo, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207551 · Cited by 392
Fecal microbiota transplantation
Vindigni, S. M., & Surawicz, C. M. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.012 · Cited by 283
An overview of fecal microbiota transplantation: techniques, indications, and outcomes
Brandt, L. J., & Aroniadis, O. C. (2013) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.03.1329 · Cited by 268
Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review
Rossen, N. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5359 · Cited by 248
Fecal microbiota transplantation broadening its application beyond intestinal disorders
Xu, M.-Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.102 · Cited by 231
Gut microbiota: Implications in Parkinson's disease
Parashar, A., & Malairaman, U. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.02.002 · Cited by 237
Collins, S. M., Kassam, Z., & Berčík, P. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.004 · Cited by 214
Fecal Transplants: What Is Being Transferred?
Bojanova, D. P., & Bordenstein, S. R. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002503 · Cited by 191
Adverse events in faecal microbiota transplant: a review of the literature
Baxter, M., & Colville, A. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.10.024 · Cited by 188
The interplay between host immune cells and gut microbiota in chronic inflammatory diseases
Kim, D.-H., Zeng, M. Y., & Núñez, G. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.24 · Cited by 191
Fecal microbiota transplantation beyond Clostridioides difficile infections
Wortelboer, K., Nieuwdorp, M., & Herrema, H. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.066 · Cited by 163
Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases
Biazzo, M., & Deidda, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144119 · Cited by 172
Microbiome therapeutics: exploring the present scenario and challenges
Yadav, M., & Chauhan, N. S. (2021) · Gastroenterology report · doi:10.1093/gastro/goab046 · Cited by 164
“1 Clostridium difficile infection [35] 2 Recurrent Clostridium difficile infection [38] 3 Irritable bowel syndrome [54, 55] 4 Insulin sensitivity [42] 5 Recurrent urinary-tract infection [43] 6 Alcoholic liver disease [44] 7 Autism [47] 8 Multiple sclerosis [56] 9 Parkinson’s disease [57] 10 Cancer [48] 11 Pseudomembr…”
BackgroundImplications of Gut Microbiota in Neurodegenerative Diseases
Zhang, H., Chen, Y., Wang, Z., Xie, G., Liu, M., Yuan, B., Chai, H., Wang, W., & Cheng, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.785644 · Cited by 161
Dutta, S., Verma, S., Jain, V., Surapaneni, B. K., Vinayek, R., Phillips, L. E., & Nair, P. P. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19044 · Cited by 150
Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS
Makkawi, S., Camara-Lemarroy, C. R., & Metz, L. M. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000459 · Cited by 144
A clinical update on the significance of the gut microbiota in systemic autoimmunity
Rosser, E. C., & Mauri, C. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.009 · Cited by 142
Sha, S., Liang, J., Chen, M.-T., Xu, B., Liang, C., Wei, N., & Wu, K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12699 · Cited by 134
Bicknell, B. T., Liebert, A. D., Borody, T. J., Herkes, G., McLachlan, C. S., & Kiat, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119577 · Cited by 135
“Three MS patients were treated with FMT for constipation, all of whom improved in their symptoms and one of whom regained the ability to walk and went into remission for 15 years [409].”
Self-citationWang, H., Wang, G., Banerjee, N., Liang, Y., Du, X., Boor, P. J., Hoffman, K. L., & Khan, M. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651191 · Cited by 126
Fecal Microbiota Transplantation
Borody, T. J., & Campbell, J. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2012.08.008 · Cited by 143
Self-citationKhor, B., Snow, M., Herrman, E., Ray, N., Mansukhani, K., Patel, K. A., Said-Al-Naief, N. A. H., Maier, T., & Machida, C. A. (2021) · Microorganisms · doi:10.3390/microorganisms9030496 · Cited by 123
“A summary of three cases describing patients with multiple sclerosis (MS) and ac‐ companying severe chronic constipation found that these individuals experienced signif‐ icantly improved GI and neurological symptoms following FMT [70].”
BackgroundWang, Y., Zhang, S., Borody, T. J., & Zhang, F. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002339 · Cited by 115
Self-citationInvited Review: From nose to gut – the role of the microbiome in neurological disease
Bell, J. S., Spencer, J. I., Yates, R. L., Yee, S. A., Jacobs, B. M., & DeLuca, G. C. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12520 · Cited by 111
Parodi, B., & de Rosbo, N. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718220 · Cited by 114
Vrieze, A., de Groot, P. F., Kootte, R. S., Knaapen, M., van Nood, E., & Nieuwdorp, M. (2013) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.03.003 · Cited by 102
Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain
Xu, H., Huang, H., Zhou, Y., Zhao, H., Xu, J., Shou, D., Liu, Y., Zhou, Y., & Nie, Y. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/6699268 · Cited by 100
Ethical Issues in Fecal Microbiota Transplantation in Practice
Ma, Y., Liu, J., Rhodes, C., Nie, Y., & Zhang, F. (2017) · The American Journal of Bioethics · doi:10.1080/15265161.2017.1299240 · Cited by 92
“Usually the patient has been cleared for treatment of a specific disease (Borody et al., 2011; Borody and Campbell 2012).”
BackgroundArmstrong, C. W., McGregor, N., Lewis, D. P., Butt, H. L., & Gooley, P. R. (2016) · Metabolomics · doi:10.1007/s11306-016-1145-z · Cited by 90
Engen, P. A., Zaferiou, A. M., Rasmussen, H. E., Naqib, A. D., Green, S. J., Fogg, L., Forsyth, C. B., Raeisi, S., Hamaker, B. R., & Keshavarzian, A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00978 · Cited by 90
Matheson, J.-A. T., & Holsinger, R. M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021001 · Cited by 96
The gut microbiome and microbial translocation in multiple sclerosis
Mirza, A., & Mao‐Draayer, Y. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.03.001 · Cited by 92
Bested, A. C., Logan, A. C., & Selhub, E. M. (2013) · Gut Pathogens · doi:10.1186/1757-4749-5-4 · Cited by 84
Therapies to modulate gut microbiota: Past, present and future
Gupta, A., Saha, S., & Khanna, S. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i8.777 · Cited by 84
de Vos, W. M. (2013) · Microbial Biotechnology · doi:10.1111/1751-7915.12047 · Cited by 84
“In addition, indications exist for the successful treatment of chronic fatigue syndrome (Borody et al., 2012) and multiple sclerosis (Borody et al., 2011) but these are only based on single studies, as has been reviewed recently (Vrieze et al., 2013).”
BackgroundGut-Microbiota, and Multiple Sclerosis: Background, Evidence, and Perspectives
Altieri, C., Speranza, B., Corbo, M. R., Sinigaglia, M., & Bevilacqua, A. (2023) · Nutrients · doi:10.3390/nu15040942 · Cited by 84
Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome
Camara-Lemarroy, C. R., Metz, L. M., & Yong, V. W. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i37.4217 · Cited by 77
Microbiome Gut-Brain-Axis: Impact on Brain Development and Mental Health
Ramadan, Y. N., Alqifari, S. F., Alshehri, K., Alhowiti, A., Mirghani, H. O., Alrasheed, T., Aljohani, F., Alghamdi, A. M., & Hetta, H. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04846-0 · Cited by 100
Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye
Watane, A., Cavuoto, K. M., Rojas, M., Dermer, H., Day, J. O., Banerjee, S., & Galor, A. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.06.022 · Cited by 69
Lorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature
Cohen, N. A., & Maharshak, N. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4535-9 · Cited by 66
The hygiene hypothesis at a glance: Early exposures, immune mechanism and novel therapies
Alexandre-Silva, G. M., de Souza, P. A. B., Oliveira, A. C. S., Cerni, F. A., Zottich, U., & Pucca, M. B. (2018) · Acta Tropica · doi:10.1016/j.actatropica.2018.08.032 · Cited by 67
Bakker, G. J., & Nieuwdorp, M. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0008-2017 · Cited by 61
Role of Microbiome and Antibiotics in Autoimmune Diseases
Vangoitsenhoven, R., & Cresci, G. (2020) · Nutrition in Clinical Practice · doi:10.1002/ncp.10489 · Cited by 61
The Gut-Brain-Immune Axis in Autism Spectrum Disorders: A State-of-Art Report
Puricelli, C., Rolla, R., Gigliotti, C. L., Boggio, E. M., Beltrami, E., Dianzani, U., & Keller, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.755171 · Cited by 64
“Firstly experimented in the field of gastroenterology, FMT has shown promise also in the therapy of extraintestinal disorders, includingmetabolic syndrome (171), multiple sclerosis (172), Parkinson’s disease (173), neurodevelopmental disorders like ASD (174), and even cancer (175, 176).”
BackgroundGut microbiome and multiple sclerosis: New insights and perspective
Amini, M. E., Shomali, N., Bakhshi, A., Rezaei, S., Hemmatzadeh, M., Hosseinzadeh, R., Eslami, S., Babaie, F., Aslani, S., Torkamandi, S., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107024 · Cited by 54
Ertürk-Hasdemir, D., Ochoa‐Repáraz, J., Kasper, D. L., & Kasper, L. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662807 · Cited by 51
Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications
Wang, X., Liang, Z., Wang, S., Ma, D., Zhu, M., & Feng, J. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210629145351 · Cited by 49
Modification of the gut microbiome to combat neurodegeneration
Sasmita, A. O. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0005 · Cited by 50
Microbiota and epigenetics: promising therapeutic approaches?
El-Sayed, A., Aleya, L., & Kamel, M. S. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-15623-6 · Cited by 43
Kraeuter, A.-K., Phillips, R., & Sarnyai, Z. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00799 · Cited by 43
Kumar, N., Sahoo, N. K., Mehan, S., & verma, B. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104547 · Cited by 41
Lee, W. J., Lattimer, L., Stephen, S., Borum, M. L., & Doman, D. B. (2015) · PubMed · Cited by 39
Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
Ткач, С. М., Dorofeyev, A., Kuzenko, I., Boyko, N., Falalyeyeva, T. M., Boccuto, L., Scarpellini, E., Kobyliak, N. M., & Abenavoli, L. (2022) · Medicina · doi:10.3390/medicina58010084 · Cited by 39
Chatterjee, A., Kumar, S., Sarkar, S. R., Halder, R., Kumari, R., Banerjee, S., & Sarkar, B. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109622 · Cited by 36
Deidda, G., & Biazzo, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.753915 · Cited by 37
Adverse events of fecal microbiota transplantation: a metaanalysis of high-quality studies
Michailidis, L. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0655 · Cited by 34
“Annals of Gastroenterology 34 FMT use in other neuropsychiatric, autoimmune and metabolic disease states, such as anorexia [35,36], multiple sclerosis [37], autism [38], sepsis [39], and others [40].”
BackgroundCracking Brain Diseases from Gut Microbes-Mediated Metabolites for Precise Treatment
Gong, Y., Chen, A., Zhang, G., Shen, Q., Zou, L., Li, J., Miao, Y., & Liu, W. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85259 · Cited by 34
“The patients' gut and neurological symptoms were improved, and they speculated that FMT eliminated occult gut pathogens that caused MS [192].”
BackgroundFecal Microbiota Transplantation in Gastrointestinal and Extraintestinal Disorders
Ianiro, G., Segal, J. P., Mullish, B. H., Quraishi, M. N., Porcari, S., Fabiani, G., Gasbarrini, A., & Cammarota, G. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0061 · Cited by 31
Microbiome and immune-mediated dry eye: a review
Watane, A., Raolji, S., Cavuoto, K. M., & Galor, A. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2021-000956 · Cited by 33
Microbiota-targeted therapies in inflammation resolution
Strati, F., Lattanzi, G., Amoroso, C., & Facciotti, F. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101599 · Cited by 31
Melamed, E., Palmer, J. L., & Fonken, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1019877 · Cited by 26
How to Manipulate the Microbiota: Fecal Microbiota Transplantation
Fuentes, S., & de Vos, W. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-31248-4_10 · Cited by 28
Schmidt, E. K. A., Raposo, P. J. F., Madsen, K. L., Fenrich, K. K., Kabarchuk, G., & Fouad, K. (2021) · Biology · doi:10.3390/biology10040254 · Cited by 24
Mahmoudi, H., & Hossainpour, H. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_131_22 · Cited by 25
“It is hoped that such fortuitous findings can stimulate a new direction in neurological research.[64]”
BackgroundInfluentialBrandt, L. J. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000346 · Cited by 22
Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
Zerdan, M. B., Niforatos, S., Nasr, S., Nasr, D., Ombada, M., John, S., Dutta, D., & Lim, S. H. (2022) · Cancers · doi:10.3390/cancers14030691 · Cited by 22
The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly
Cheng, Y., & Fischer, M. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0143-1 · Cited by 21
Tsai, Y.-W., Dong, J.-L., Jian, Y.-J., Fu, S., Chien, M., Liu, Y., Hsu, C.-Y., & Sytwu, H. (2021) · Microorganisms · doi:10.3390/microorganisms9091930 · Cited by 21
Vindigni, S. M., Broussard, E. K., & Surawicz, C. M. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2013.832501 · Cited by 21
Disentangling What We Know About Microbes and Mental Health
Reid, G. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00081 · Cited by 21
Tsogka, A., Kitsos, D. K., Stavrogianni, K., Giannopapas, V., Chasiotis, A. K., Christouli, N., Tsivgoulis, G. K., Tzartos, J. S., & Giannopoulos, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247610 · Cited by 21
“Borody and colleagues [29] presented three case reports of patients with MS, described diagnostically as “atypical MS”, which received a fixed number of fecal transplantations and were prospectively followed up.”
BackgroundFecal Microbiota Transplantation for Fibromyalgia: A Case Report and Review of the Literature
Thurm, T., Ablin, J. N., Buskila, D., & Maharshak, N. (2017) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2017.74015 · Cited by 19
Woloszynek, S., Pastor, S. J., Mell, J. C., Nandi, N., Sokhansanj, B. A., & ROSEN, G. L. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.01.003 · Cited by 20
More than just a number: the gut microbiota and brain function across the extremes of life
Nuzum, N. D., Deady, C., Kittel‐Schneider, S., Cryan, J. F., O’Mahony, S. M., & Clarke, G. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2418988 · Cited by 22
“307 ,308 A pilot FMT trial in MS patients (N = 9) were given monthly FMTs for 6-months.”
Nemati, M. H., Yazdanpanah, E., Kazemi, R., Orooji, N., Dadfar, S., Oksenych, V., & Haghmorad, D. (2025) · Biology · doi:10.3390/biology14040435 · Cited by 21
“One preliminary abstract reported positive effects of FMT on the neurological disorders of three MS patients [108].”
Trasplante de microbiota fecal
de Paredes, A. G. G., de Santiago, E. R., Aguilera, L., Ferre‐Aracil, C., & López–Sanromán, A. (2014) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2014.07.010 · Cited by 17
Gunardi, T. H., Susantono, D. P., Victor, A. A., & Sitompul, R. (2021) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v16i4.9754 · Cited by 17
Laeeq, T., Vongsavath, T., Tun, K. M., & Hong, A. S. (2023) · Microorganisms · doi:10.3390/microorganisms11122840 · Cited by 15
Ferroptosis: A New Pathway in the Interaction between Gut Microbiota and Multiple Sclerosis
Jian, J., & Wei, J. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26265 · Cited by 14
Faecal microbiota transplantation—A clinical view
Mattner, J., Schmidt, F., & Siegmund, B. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2016.02.003 · Cited by 12
Mandato, C., Colucci, A., Lanzillo, R., Staiano, A., Scarpato, E., Schiavo, L., Operto, F. F., Serra, M. R., Monaco, C. D., Napoli, J. S., et al. (2023) · Children · doi:10.3390/children10061022 · Cited by 15
“Last but not least, fecal microbiota transplantation (FMT) represents a further interesting approach to modulate GM [201,202].”
BackgroundTorres‐Chávez, M., Torres-Carrillo, N. M., Moreal‐Lugo, A., Rancurello, S. G., Murugesan, S., Gutiérrez-Hurtado, I. A., Beltran-Ramirez, J. R., Sandoval‐Pinto, E., & Torres‐Carrillo, N. (2023) · Biomedical Reports · doi:10.3892/br.2023.1675 · Cited by 13
Xu, D., Ren, L., Zhang, W., Wu, S., Yu, M., He, X., & Wei, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33214 · Cited by 12
“Borody et al.[9] used FMT to treat three MS patients with chronic constipation for up to 15 years, finding a gradual improvement in neurological symptoms and recovery of walking ability in all cases; two patients regained urinary function and the progress of one patient ’ s condition was halted.”
BackgroundWu, D., Zhang, C., Liu, Y., Yao, J., Yang, X., Wu, S., Du, J., & Yang, X. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.02.005 · Cited by 14
Fecal Microbiota Therapy With a Focus on Clostridium difficile Infection
Brandt, L. J. (2017) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000511 · Cited by 12
Clostridioides difficile and neurological disorders: new perspectives
Biazzo, M., Allegra, M., & Deidda, G. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.946601 · Cited by 11
Overview of the Gut Microbiome
Blackmer‐Raynolds, L., & Sampson, T. R. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771463 · Cited by 11
Nezhadi, J., Fadaee, M., Ahmadi, S., & Kafil, H. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39047 · Cited by 13
Merchak, A. R., Bolen, M. L., Tansey, M. G., & Menees, K. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00476 · Cited by 12
Clancy, A. K., Gunaratne, A. W., & Borody, T. J. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.653653 · Cited by 12
“For example, case reports have shown improvements in Parkinson’s Disease (5), Multiple Sclerosis (6), Alopecia (7), Depression, and Anxiety (8).”
ResultSelf-citationIf microbial ecosystem therapy can change your life, what's the problem?
Ettinger, G., Burton, J. P., & Reid, G. (2013) · BioEssays · doi:10.1002/bies.201300015 · Cited by 11
Hazan, S., Haroon, J. M., Jordan, S., & Walker, S. J. (2024) · Journal of Medical Cases · doi:10.14740/jmc4209 · Cited by 11
Multiple sclerosis and faecal microbiome transplantation: are you going to eat that?
Wing, A. C., & Kremenchutzky, M. (2018) · Beneficial Microbes · doi:10.3920/bm2018.0029 · Cited by 10
Metadata
- Authors
- Borody, T., Leis, S., Campbell, J., Torres, M., & Nowak, A.
- Affiliations
- Centre For Digestive Diseases (AU)
- Venue
- American Journal of Gastroenterology
- Published
- 2011-10
- Volume
- 106
- Pages
- S352
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2978324930
- Cited by
- 149
- References
- 0
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 11 · 2023: 17 · 2022: 15 · 2021: 22 · 2020: 14 · 2019: 7 · 2018: 8 · 2017: 16 · 2016: 9 · 2015: 7 · 2014: 5 · 2013: 9 · 2012: 2
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- fecal microbiota transplantation, multiple sclerosis, chronic constipation, proctalgia fugax, gut microbiota, urinary catheter removal, relapsing-remitting multiple sclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review